Modality
Multispecific
MOA
JAK1/2i
Target
JAK2
Pathway
mTOR
ThymomaUCCervical Ca
Development Pipeline
Preclinical
~Jun 2015
→ ~Sep 2016
Phase 1
~Dec 2016
→ ~Mar 2018
Phase 2
Jun 2018
→ Mar 2027
Phase 2Current
NCT04098504
581 pts·Thymoma
2018-06→2027-03·Not yet recruiting
581 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-275mo agoPDUFA· Cervical Ca
2027-03-0611mo awayPh3 Readout· Thymoma
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P2/3
Not yet…
Catalysts
PDUFA
2025-10-27 · 5mo ago
Cervical Ca
Ph3 Readout
2027-03-06 · 11mo away
Thymoma
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04098504 | Phase 2/3 | Thymoma | Not yet recr... | 581 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Fixanesiran | AbbVie | Preclinical | RET | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 |